Chief Executive Officer - Chairman of the board
Current board member and advisor for several biotech companies, Gilles Avenard is Medical Doctor and was the co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. He was notably involved in the development of several innovative medicines through to their official registration on both European and North-American territories. Before that, he worked as Project Director for Hoechst Marion Roussel (Sanofi) and was Medical Director of Bio-Transfusion (LFB).
After an extensive professional experience at a court-appointed representative’s office in Paris, Nacera Brouttelande joined Acticor Biotech in June 2018 where she works as office manager notably dealing with the company’s administrative, legal and accounting follow-up.
Clinical Trial Lead
Graduated in musicology, Vanessa started her professional life as a self-employed music-therapist for children and adults with learning disabilities for 8 years. Subsequently, she moved to the United Kingdom where she followed an English course in Cambridge and became a translator and medical interpreter for French-speaking patients.
Upon her return in France, she started working for a CRO: First on the executive side where she assisted the CEO with contracts, invoicing, organization of customer events, QC and translations etc. Then she moved to the operational side as CTA and senior CTA, and for 4 years she worked on various projects in oncology, in pulmonology and ophthalmology. She is committed and know well the ICH_GCP legislation as well as the innovation and development regulations. To continue her education and experience, she has just completed a BTS in management and an MBA in business development.
Vanessa joined Acticor Biotech as Clinical Trial Lead.
Andrea Comenducci, MD, Medical Director at Acticor Biotech. Educated as a General Practitioner, Andrea has a 25-year experience in the pharmaceutical industry. He assumed various functions from International Project leader and Senior Medical Advisor to Medical Director in medium and large companies. His preferred therapeutic area is the cardiovascular field in which he has vast experience in coronary diseases, high blood pressure, heart failure, atherosclerosis acquired in large worldwide clinical trials such as the GUSTO V-TIMI 14 study, STABILITY and SOLID-TIMI 52 studies. In November 2018, Andrea joined Acticor Biotech with the role of Medical Director in order to take up new exciting challenges in acute ischemic stroke and pulmonary embolism.
Chief Financial Officer
CEO and Founder of Agile Capital Markets; Advisor of several biotech & medtech companies (among which EOS imaging, Cellnovo, PKvitality), Eric raised over 200M€ in public and private fund raising. He was previously CFO of Mauna Kea Technologies (Euronext®: MKEA), Hybrigenics (Euronext®: ALHYG) and Teva Pharmaceuticals France (NASDAQ®: TLV). He led 2 IPO on Euronext® raising 62M€. He was also Head of Hybrigenics Business Services and Head of Operations (R&D and Production) at Mauna Kea Technologies.
Founder of 3Biotech, Olivier Favre-Bulle specializes in Pharmaceutical Development of Large and Small Molecules. After a Ph.D in Bioengineering, he started his career as project manager in Biological Drugs development at Rhône-Poulenc. He was site manager and European Head of Drug Development for Covance, and he also directed the NNE Pharmaplan France, a subsidiary of Novo Nordisk.
Analytical Project Manager
With a professional bachelor’s degree in pharmaceutical industries, focusing on biotechnology. P. Ferlan started her career in Sanofi’s R&D laboratories. She works on analytical methods development, stability studies and functional characterization of ACT017.
Head of Finance and Administration
With a Master’s degree in Accounting and Finance, Aymeric was an Audit Manager at Grant Thornton for 7 years. He worked on listed and non-listed companies and specialized in the Biotech industry. He joined Acticor Biotech in January 2019 as Administrative and Finance Manager.
Regulatory Affairs Manager
After a master degree in pharmaceutical biotechnology and innovative therapy, Jessica (PharmD) joined Acticor Team in November 2019 as Regulatory and Clinical Associate after completing her end of study internship in Regulatory Affairs and CMC departments. She monitors and participates in regulatory activities of clinical projects.
Head of Regulatory Affairs
PharmD., Master in International Drug Development and Registration. Laurie Jullien started at Genentech (USA) in Product Drug Development and was then appointed Regulatory Affairs Labelling Manager at Roche (UK). She joined Acticor Biotech in 2016 and started as Regulatory and Quality Manager, working from the non-clinical studies to the Phase 1 trial . In 2018 she was appointed Head of Regulatory Affairs and Quality , ensuring the regulatory strategy and the development of the quality policy of the company. From November 2020, she is taking the role of Head of Regulatory Affairs full time, working on the global regulatory strategy and the management of the regulatory department.
Pharmaceutical Development Associate
With a Master degree of Biotechnology Engineering from Sup’Biotech and a PhD in Bioprocess Enginneeing from CentraleSupélec school (previously Centrale Paris), Angéla started her career in the development and optimisation of cell culture in bioreactor within the Chair of Biotechnology of CentraleSupélec. She joined Acticor Biotech in March 2020 as Pharmaceutical Development Associate.
Communication and IT Assistant
After a bachelor’s degree in sciences and management technologies (STMG), Antoine started in the field of communication. He joined Acticor Biotech as a communications assistant on a work-study program in September 2020.
Chief Operating Officer and Chief Scientific Officer
Sophie has over 20 years’ experience in start-ups and mid-size companies within the biotechnology areas. She has a strong expertise in oncology, immunology and virology. Sophie has managed a number of innovative R&D projects from the proof-of-concept to early clinical development. In her previous positions, Sophie was Vice-President Research and Early Clinical Development at PEP-Therapy, responsible for the development of peptide drug candidates and their biomarkers up to clinical trials. She was responsible for nonclinical R&D activities at InnaVirVax, developing innovative immune-based treatments for infectious diseases. She was Head of translational programs in oncology at Gustave Roussy Cancer Center, where she coordinated research programs and implemented innovative technology platforms dedicated to translational research. During her carrier, Sophie held various positions, at INSERM, CEA, Centre d’Immunologie Pierre Fabre, VIRalliance and Stallergenes. Sophie holds a PhD in immunology from Paris VII Denis Diderot university. She is (co-)author of about 20 scientific publications and co-inventor of 9 patents.
Head of Pharmaceutical & Non-Clinical Development
Master degree of Biotechnology Engineering with a focus on R&D and Health, Kristell Lebozec has a 2 years experience in academic laboratories (Institut Gustave Roussy and Centre de Recherche des Cordeliers) and in the industry (DNA Therapeutics and I-Stem). She joined Acticor Biotech in 2015 and was in charge of selecting ACT017 expression system and of the functional characterization of product. She is now managing the pharmaceutical and non-clinical development.
Global Clinical Operations Director
Adeline Meilhoc has spent her career in the clinical development of pharmaceutical products in pharmaceutical companies and contract research organizations – UCB Pharma, Parexel Inc., Cegedim Sgtrategic Data, both as VP Medical Affairs and Clinical Operations and as VP Business Development. She has built several departments in clinical trial feasibility, study start-up and medical imaging as well as commercial and marketing development.
Specializing in business relationships, she has spent the last few years developing Marketing & Sales strategies in various eClinical tools for Healthcare Professionals and Medical Device companies, in addition to her own businesses. Her solid expertise in Real World Evidence and in the operational aspect of market access broadens her vision of drug development and launch. She is a clinical psychologist by training at the ICP – EPP where she obtained a thesis in addiction and depression with honors. She brings now her expertise to Acticor Biotech in the direction of clinical trials and team management.
Clinical Operations Trainer
Stéphanie PAUL, Clinical Research Nurse Trainer at Acticor Biotech, background of study research nurse; she has more than 13 years of experience in a clinical research center in CHRU from Brest.
She assumed various functions from study coordinator in different therapeutic domains: respiratory, thromboembolic diseases, vascularitis and neurological area. She supervised both French and international trials, and realized all the technical care, in respect of GCP.
She comes from hospital so she could be a veritable resource for the training staff.
Chief Medical Officer
Dr Plétan is an expert in clinical development within the pharmaceutical industry. He previously held leadership positions at Roche, Pfizer, Sanofi and Pierre Fabre. Before joining Acticor Biotech, Dr Plétan served as head of the Medical Division and was a board member of the Foundation at Roche France and member of the Global Medical Affairs Committee at Hoffman La Roche Ltd (Switzerland). Prior to these activities, he was also vice-president, head of Medical and Scientific Division and board member of the Foundation at Pfizer.
Head of Quality Assurance
PharmD. – Master in Quality Assurance – Pharmaceutical Products.
Victoria Rutman has 3 years of hands-on experience in the pharmaceutical industry. Primarily, at Orphan Europe, she worked in the Quality Assurance Department before being promoted as a Packaging and Equipment project manager.
She is in charge of the Quality system management at Acticor.
Senior Clinical Project Manager
Anouar has more than 20 years of experience working in the pharmaceutical industry. He began his career at Gustave Roussy Institute, then ICON Clinical research and Nanobiotix, holding various positions and acting as “Global Clinical Project Manager” and “Associate Director Clinical Operations” afterwards.